Pipeline

Patient Resources

The following organizations provide educational resources and support research to help people living with rare, inherited diseases involving the liver and genetic cancers.

 

Rare Genetic Diseases of the Liver

Global Genes is a leading rare disease advocacy organization dedicated to eliminating the challenges of rare diseases by spreading awareness, and providing education and resources to impact affected patients and their families.

Dicerna is proud to be a member of the RARE Corporate Alliance™, which is a collaborative group of rare disease stakeholders, including pharmaceutical companies, health-related organizations, industry and academia. The Alliance is committed to advancing efforts that benefit the rare disease community and its constituents.

Learn More


NORD provides advocacy, education and other services to improve the lives of all people affected by rare diseases.

Learn More


The Rare Disease United Foundation (RDUF) is a non-disease-specific, state-based organization currently with communities in Rhode Island and Massachusetts. The Foundation addresses challenges faced by people living with rare diseases, including: inaccurate or no diagnosis, lack of awareness, insurance and/or other reimbursement issues, and isolation. The RDUF’s mission is to work on these issues at the state level by providing support and information to patients’ families, and by advocating and raising awareness of rare diseases in the classroom, the medical community and the general public.

Learn More


 

PH1

The OHF is the only foundation in the world dedicated to improving the care and treatment and finding a cure for oxalosis, primary hyperoxaluria (including PH1) and related stone diseases.

Learn More


The Mayo Clinic Hyperoxaluria Center is a clinical care and research center staffed by physician scientists devoted to the study of primary hyperoxaluria. The goals of the center are to provide a resource for the diagnosis and care of patients with primary hyperoxaluria, to discover factors that predict or determine loss of kidney function in patients with primary hyperoxaluria, and to develop effective treatments.

Learn More


The Rare Kidney Stone Consortium facilitates cooperative exchange of information and resources among investigators, clinicians, and patients, and researchers in order to improve care and outcomes for patients with rare stone diseases.  The consortium promotes ready availability of diagnostic testing, pooling of clinical experiences, and availability of tissue banks in order to advance the science.

Learn More


 

The mission of the ALF is to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease, including liver cancer.

Learn More


The mission of the Cancer Resource Foundation is to advocate and provide support for the prevention, early detection, diagnosis, treatment, and survivorship of cancer through patient assistance, education and research.

Learn More

 


 

Additional Reading

 

Liver Disease

Rare Kidney Stone Consortium: Primary Hyperoxaluria

American Cancer Society: Risk Factors for Liver Disease

Review article: Viral hepatitis, non-alcoholic fatty liver disease and alcohol as risk factors for hepatocellular carcinoma (PDF)

This article reviews the viral characteristics associated with increased risk for development of hepatoceullular carcinoma (HCC) and the role of antiviral therapy in decreasing risk of HCC in those with viral hepatitis and cirrhosis. Association of alcoholic cirrhosis and non-alcoholic fatty liver disease with liver cancer will be reviewed as well as possible measures to decrease the risk of HCC in these highly prevalent populations.

This article provides an overview of Primary Hyperoxaluria type 1, including its epidemiology, different forms of the diseases and its genetic makeup. The article also presents information on the diagnosis, management and current treatment options for the condition, including transplantation and dialysis. Finally, the article provides preclinical data and possible therapeutic developments in the coming years as a result of research currently underway. Cochat, P, Rumsby, G. Primary hyperoxaluria. The New England Journal of Medicine 2013; 369(7): 649-658.